Aimmune Therapeutics, Inc.

Rivus Pharmaceuticals Strengthens Leadership Team Ahead of Critical Phase 2b MASH Trial Results

a month ago

• Rivus Pharmaceuticals has appointed David Grainger, Ph.D., as Chairman of Development and Meg Fitzgerald, J.D., as Chief Legal Officer while establishing a new office in South San Francisco. • The company is advancing its novel Controlled Metabolic Accelerators (CMAs), led by HU6, which has shown promising Phase 2a results in treating obesity-related conditions without muscle mass loss. • Rivus is approaching a critical milestone with the imminent readout of its Phase 2b M-ACCEL study in metabolic dysfunction-associated steatohepatitis (MASH), potentially advancing HU6 to pivotal trials.